Kirsten Schmitt
Medical · Traverse City, MINPI 1528121811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 505 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,758, 6.4 times the $430 reported in 2021. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Amgen$1K
- Sanofi$709
- Takeda Pharmaceuticals U.S.A., Inc.$501
- Regeneron Healthcare Solutions, Inc.$436
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$1251%
- Food & beverage$9,98398%
- Other$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 100 | $2,177 |
| GSK | 112 | $1,606 |
| Amgen(2 entities) | 52 | $1,023 |
| Sanofi | 26 | $709 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $501 |
| Regeneron Healthcare Solutions, Inc. | 18 | $436 |
| Novartis | 18 | $426 |
| Genentech USA, Inc. | 24 | $405 |
| AbbVie | 16 | $397 |
| CSL Behring | 19 | $393 |
| Pfizer | 23 | $345 |
| Pharming Healthcare, Inc. | 7 | $246 |
| Aimmune Therapeutics, Inc. | 4 | $189 |
| Boehringer Ingelheim | 7 | $159 |
| Grifols USA, LLC | 6 | $140 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $127 |
| Kaleo, Inc. | 6 | $109 |
| Organon | 4 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $101 |
| Biocryst US Sales Co., LLC | 4 | $89 |
| Ionis Pharmaceuticals, Inc. | 2 | $65 |
| LEO Pharma Inc. | 4 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Welch Allyn | 1 | $58 |
| Alk-abello, Inc | 2 | $46 |
| Blueprint Medicines Corporation | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| Dermavant Sciences, Inc. | 1 | $20 |
| Greer Laboratories, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Merck | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Hospira, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$401
- PALFORZIA$125
- TRELEGY ELLIPTA$125
- DUPIXENT$124
- XIFAXAN$101
How this compares
$10,166 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $47,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,421 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,442 |
| Ipratropium Bromide | 47 | $1,159 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $318 |
| Montelukast Sodium | 17 | $259 |
| Famotidine | 11 | $57 |
| Prednisone | 20 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,606 | $11,42116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Traverse City
- Jesse KogelmanTraverse City$21K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.